Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin α.

Honda T, Ogata S, Mineo E, Nagamori Y, Nakamura S, Bando Y, Ishii M.

Pediatrics. 2013 Mar;131(3):e928-33. doi: 10.1542/peds.2012-1466. Epub 2013 Feb 4.

2.

Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome.

Kawasaki Y, Suyama K, Ono A, Oikawa T, Ohara S, Suzuki Y, Sakai N, Hosoya M.

Pediatr Int. 2013 Oct;55(5):e139-42. doi: 10.1111/ped.12165.

PMID:
24134770
3.

Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Mori Y, Wada H, Okugawa Y, Tamaki S, Nakasaki T, Watanabe R, Gabazza EC, Nishikawa M, Minami N, Shiku H.

Clin Appl Thromb Hemost. 2001 Jan;7(1):5-9.

PMID:
11190905
4.

Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution.

Kawano N, Yoshida S, Ono N, Himeji D, Nagahiro Y, Sayaka Kawano, Yamashita K, Ikeda N, Uezono S, Ochiai H, Kawano F, Kikuchi I, Ishikawa F, Shimoda K, Ueda A, Akashi K.

J Clin Exp Hematop. 2011;51(2):101-7.

5.

Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution--an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases.

Kawano N, Tasaki A, Kuriyama T, Tahara Y, Yoshida S, Ono N, Himeji D, Yamashita K, Shibata Y, Goto T, Inoue T, Yokota-Ikeda N, Uezono S, Yuge A, Nishiguchi T, Kinjo T, Ogura Y, Beppu K, Ueda Y, Kinoshita M, Moritake H, Shimoda K, Ochiai H, Ueda A.

Intern Med. 2014;53(3):205-13.

6.

Treatment responses for disseminated intravascular coagulation in 25 children treated with recombinant thrombomodulin: a single institution experience.

Yagasaki H, Kato M, Shimozawa K, Hirai M, Nishikawa E, Okuma H, Ishii W, Imai Y, Matsumura M, Yonezawa R, Yoshikawa K, Shichino H, Chin M, Mugishima H.

Thromb Res. 2012 Dec;130(6):e289-93. doi: 10.1016/j.thromres.2012.10.004. Epub 2012 Nov 1.

PMID:
23123162
7.

The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.

Suyama K, Kawasaki Y, Miyazaki K, Kanno S, Ono A, Ohara S, Sato M, Hosoya M.

Nephrol Dial Transplant. 2015 Jun;30(6):969-77. doi: 10.1093/ndt/gfv004. Epub 2015 Feb 17.

PMID:
25694534
8.
9.

[Hemolytic uremic syndrome in adults].

Hertig A, Ridel C, Rondeau E.

Nephrol Ther. 2010 Jul;6(4):258-71. doi: 10.1016/j.nephro.2010.03.002. Epub 2010 Apr 15. French.

PMID:
20399168
10.

[The efficacy of early use of recombinant soluble thrombomodulin for disseminated intravascular coagulation complicated with hematologic malignancies].

Usami M, Kuroda H, Yoshida M, Sakamoto H, Shimoyama S, Kanari Y, Yamada M, Abe T, Fujii S, Maeda M.

Rinsho Ketsueki. 2015 Jun;56(6):673-80. doi: 10.11406/rinketsu.56.673. Japanese.

PMID:
26256878
12.

Efficacy of recombinant human soluble thrombomodulin in severe postpartum hemorrhage with disseminated intravascular coagulation.

Sugawara J, Suenaga K, Hoshiai T, Sato T, Nishigori H, Nagase S, Yaegashi N.

Clin Appl Thromb Hemost. 2013 Sep;19(5):557-61. doi: 10.1177/1076029612443305. Epub 2012 Apr 11.

PMID:
22496090
13.

Diagnosis and classification of hemolytic uremic syndrome: the Hungarian experience.

Reusz GS, Szabó AJ, Réti M, Györke Z, Szilágyi Á, Farkas P, Prohászka Z.

Transplant Proc. 2011 May;43(4):1247-9. doi: 10.1016/j.transproceed.2011.03.071.

PMID:
21620101
14.

[Treatment of hemolytic uremic syndrome after acute stage].

Ye LY, Yu ZH, Huang ZX, Chen XM, Ren RN, Chen GM, Wang CF, Xia GZ, Huang J, Wang FJ.

Zhonghua Er Ke Za Zhi. 2006 Mar;44(3):206-9. Chinese.

PMID:
16624060
15.

In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models.

Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T.

Shock. 2010 Mar;33(3):282-8. doi: 10.1097/SHK.0b013e3181b0ef7b.

PMID:
19536047
16.

[Experience in the treatment with recombinant thrombomodulin on disseminated intravascular coagulation with severe urinary tract infection].

Fumino M, Kurimoto K, Kinoshita N, Kato H, Arima K, Sugimura Y.

Hinyokika Kiyo. 2012 Feb;58(2):71-4. Japanese.

17.

Soluble thrombomodulin attenuates sinusoidal obstruction syndrome in rat through suppression of high mobility group box 1.

Nakamura K, Hatano E, Miyagawa-Hayashino A, Okuno M, Koyama Y, Narita M, Seo S, Taura K, Uemoto S.

Liver Int. 2014 Nov;34(10):1473-87. doi: 10.1111/liv.12420. Epub 2014 Feb 6.

PMID:
24498917
18.

Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation.

Uni M, Yoshimi A, Maki H, Maeda D, Nakazaki K, Nakamura F, Fukayama M, Kurokawa M.

Int J Clin Exp Pathol. 2013 May 15;6(6):1190-4. Print 2013.

19.

Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.

Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI.

Pediatrics. 2005 Jun;115(6):e673-80.

PMID:
15930195
20.

Hemolytic uremic syndrome in children in Puerto Rico: a rare disease with atypical features.

Pedrogo-Rodríguez Y, Pérez-Rodríguez JO, Bonilla-Felix M.

Bol Asoc Med P R. 2008 Apr-Jun;100(2):14-6.

PMID:
19227723
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk